Azd9291

Manufactured by AstraZeneca

Sourced in United Kingdom

AZD9291 is a laboratory equipment product developed by AstraZeneca. It is designed to perform specific functions in a research or testing environment, but a detailed description of its core function cannot be provided while maintaining an unbiased and factual approach. Further information may be available from the manufacturer.

Automatically generated - may contain errors

Lab products found in correlation

3 protocols using azd9291

Investigating Receptor Signaling Pathways

Check if the same lab product or an alternative is used in the 5 most similar protocols

The following antibodies were used according to the protocols supplied by the manufacturers: anti-pERK1/2 (#9101, Cell Signaling Technology, Danvers, MA, USA), anti-ERK1/2 (#4695, Cell Signaling Technology), anti-GAPDH (ENM0040, Elabscience Biotechnology Inc., Houston, TX, USA), anti-pEGFR (12A3) (sc-57542, Santa Cruz Biotechnology Inc., Dallas, TX, USA), anti-EGFR (C-2) (sc-377229, Santa Cruz Biotechnology Inc.), anti-pAKT (#9271, Cell Signaling Technology), anti-AKT (#9272, Cell Signaling Technology), anti-Cyclin D1 (sc-753, Santa Cruz Biotechnology Inc.), anti-p21 (sc-397, Santa Cruz Biotechnology Inc.), and anti-beta Tubulin (Sigma), anti-alpha actin (Sigma). All the secondary antibodies (HRP-conjugated anti-rabbit and anti-mouse) were purchased from Santa Cruz Biotechnology Inc.
Drug formulations: gefitinib (ZD1839) and MG132 (S2619) were purchased from Selleckchem; AZD9291 was obtained from AstraZeneca; BAPTA_AM (HB0981) was from HelloBio.
Recombinant Human EGF (AF-100-15) was from PeproTech (London, UK).

Modica T.M., Dituri F., Mancarella S., Pisano C., Fabregat I, & Giannelli G. (2019). Calcium Regulates HCC Proliferation as well as EGFR Recycling/Degradation and Could Be a New Therapeutic Target in HCC. Cancers, 11(10), 1588.

+ Open protocol

+ Expand

Investigating EGFR and MET Inhibitors

Check if the same lab product or an alternative is used in the 5 most similar protocols

AZD9291 and AZD6244 were provided by AstraZeneca Pharmaceuticals. Erlotinib, gefitinib, afatinib, CO1686, crizotinib, capmatinib, cabozantinib, MGCD-265, and merestinib were purchased from Selleckchem. All drugs were dissolved in dimethyl sulfoxide (DMSO) at a 10 mM concentration and stored in small aliquots at -20°C until further use. Antibodies specific for p-EGFR (Tyr1068), EGFR, p-AkT (Ser473), AkT, p-ERK1/2 (Thr202/Tyr204), ERK1/2, p-MET (Tyr1234/1235), MET, and Ki-67 were obtained from Cell Signaling Technologies. HRAS, Maspin, and β-actin antibodies were obtained from Santa Cruz Biotechnology. HRAS siRNA, Maspin siRNA and control siRNA were purchased from Santa Cruz Biotechnology.

Ku B.M., Choi M.K., Sun J.M., Lee S.H., Ahn J.S., Park K, & Ahn M.J. (2018). Acquired resistance to AZD9291 as an upfront treatment is dependent on ERK signaling in a preclinical model. PLoS ONE, 13(4), e0194730.

+ Open protocol

+ Expand

In Vitro and In Vivo AZD9291 Assays

Check if the same lab product or an alternative is used in the 5 most similar protocols

AZD9291 for the in vitro viability assays was obtained from AstraZeneca (London, England) or Selleckchem (Houston, TX, USA). For in vitro work, AZD9291 was dissolved in DMSO. AZD9291 used in the in-vivo mouse experiments was obtained from Selleckchem. For invivo work, AZD9291 was dissolved in 0.5 % hydroxypropyl methylcellulose [HPMC] (Sigma-Aldrich).

Chen V., Iwama E., Kim I.K, & Giaccone G. (2020). Serum CRIPTO does not confer drug resistance against osimertinib but is an indicator of tumor burden in non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands), 145.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!